ArticleThe Journal of membrane biology2026
Targeting hORAI1-Mediated Calcium Influx in Triple-Negative Breast Cancer: A Computational Drug Discovery Approach.
Article in The Journal of membrane biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative subtractive genomics and molecular dynamics-based approach for drug repurposing against female genital tuberculosis.Molecular diversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Store-operated calcium entry (SOCE) is a crucial pathway that aids in restoring depleted calcium levels in the endoplasmic reticulum (ER), consequently regulating cellular calcium homeostasis. When calcium stores are low, two key proteins are activated: STIM1, which senses the calcium levels in the ER, and ORAI1, the pore-forming subunit of calcium release-activated calcium (CRAC) channels. ORAI1 is overexpressed in triple-negative breast cancer (TNBC) and regulates the transcription of genes that regulate cancer progression. The complete atomic structure of human ORAI1 (hORAI1) remains unknown, which poses a challenge for developing targeted therapies. This study modeled the closed state of hORAI1, identifying it as a potential target for disrupting calcium influx and oncogenic signaling in TNBC. A pharmacophore hypothesis derived from Mildronate analogues was utilized to screen the COCONUT database for small compounds that stabilize the closed state of hORAI1. Five promising compounds were identified: CNP0006530, CNP0006516, CNP0008628, CNP0002844, and CNP0004972. These compounds exhibited docking scores ranging from - 7.461 to - 5.393 kcal/mol and formed stable interactions with crucial residues, Glu106 and Asp110. This likely aids in stabilizing the closed conformation and inhibiting calcium influx. Molecular dynamics simulations have demonstrated the structural stability and compactness of the lead complexes. Furthermore, principal PCA/FEL analyses have validated their conformational stability within a membrane environment. These findings provide novel insights into the structural gating processes of hORAI1 and emphasize the therapeutic potential of small compounds that target its closed state to inhibit calcium-mediated carcinogenesis in TNBC.
Indexed as
Identifiers
41609838What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.